RAAS antagonist therapy for prevention of atrial fibrillation in hypertension
10.3760/cma.j.issn.1671-7368.2019.01.021
- VernacularTitle:RAAS阻滞剂预防高血压患者发生心房颤动的研究进展
- Author:
Li LI
1
;
Yanming LI
;
Weihua GUO
;
Changsheng MA
Author Information
1. 首都医科大学附属北京同仁医院心血管中心 100730
- Keywords:
Hypertension;
Atrial fibrillation;
Renin-angiotensin-aldosterone system(RAAS)
- From:
Chinese Journal of General Practitioners
2019;18(1):81-84
- CountryChina
- Language:Chinese
-
Abstract:
Hypertension is the most common and controlable risk factor of atrial fibrillation (AF).Resin-angiotensin-aldosterone system (RAAS) antagonist therapy may reduce atrial remodeling and hold promise as “upstream” therapy for AF,especially for the patients with left ventricular hypertrophy and left ventricular dysfunction.The RAAS antagonist therapy for prevention of AF in hypertensive patients needs to be further explored in large scale randomized studies.
